FHTX – foghorn therapeutics inc. (US:NASDAQ)
Stock Stats
News
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics (FHTX) was downgraded by Wall Street Zen from "b
Foghorn Therapeutics (FHTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Foghorn Therapeutics (FHTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $10.00 price target on the stock.
Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M [Seeking Alpha]
Form 4 Foghorn Therapeutics For: Apr 09 Filed by: GOTTSCHALK ADRIAN
Form S-8 Foghorn Therapeutics
Form 10-K Foghorn Therapeutics For: Dec 31
Form 8-K Foghorn Therapeutics For: Mar 11
Form 4 Foghorn Therapeutics For: Feb 23 Filed by: Maynard Ryan D
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.